Dr. Priebat is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
110 Irving St Nw
Suite 2a38
Washington, DC 20010Phone+1 202-877-2505Fax+1 202-877-8910
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 1978 - 1982
MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 1975 - 1977
Stony Brook University Health Sciences Center School of MedicineClass of 1975
Certifications & Licensure
CA State Medical License 1982 - 2025
DC State Medical License 1977 - 2024
MD State Medical License 1977 - 2017
UT State Medical License 1980 - 1986- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Top Doctors:Washington-Baltimore Castle Connolly, 2012
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2012
- Join now to see all
Clinical Trials
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Start of enrollment: 2019 Feb 08
Publications & Presentations
PubMed
- 104 citationsCorrelative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumabEmily Z. Keung, Melissa Amber Burgess, Ruth Salazar, Edwin R. Parra, Jaime Rodrigues-Canales
Clinical Cancer Research. 2020-03-15 - 806 citationsPembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialHussein Abdul-Hassan Tawbi, Melissa Amber Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze
The Lancet. Oncology. 2017-11-01 - 73 citationsCorrelation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup T...Michael Heinrich, Cathryn Rankin, Charles D. Blanke, George D. Demetri, Ernest C. Borden
JAMA Oncology. 2017-07-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
